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disease is generally marked by decline in pulmonary function over time. Recently, it has been understood that rapid deterioration in lung function and gas exchange occurs in some IPF patients and is known as acute exacerbations. The pathological features of acute exacerbations include alveolar wall edema and alveolar space flooding (14, 22) . Acute exacerbations also occur in patients with interstitial pneumonias other than IPF, such as interstitial pneumonia associated with collagen vascular disease and fibrotic nonspecific interstitial pneumonia (35, 44) . Although the etiology of an acute exacerbation is not usually apparent, this may be partly because the alveolar barriers of a fibrotic lung are chronically impaired.
The integrity of the permeability barrier of alveolar walls depends on the junctions of the alveolar epithelial and capillary endothelial cells. For example, sphingosine-1-phosphatase induces lung edema by opening tight junctions (12) , and tumor necrosis factor-␣ inhibition reduces tight junction permeability in lung tissues associated with acute lung inflammation (25) . Consequently, we hypothesized that the altered expression of tight junction molecules after lung injury might increase the permeability of alveolar walls.
Several molecular components of tight junctions, which are the apical-most components of the junction complex in vertebrate cells (40, 41) , have been identified: claudin, occludin, ZO-1, ZO-2, and ZO-3. Among these, claudin is now believed to be the backbone of the tight junction strand. Claudins are ϳ23-kDa proteins that form a family of 24 isoforms in humans and mice (10) . The expression patterns of claudins differ among organs, and this compositional heterogeneity is considered to explain the diverse properties of tight junctions. Claudin-1, claudin-3, claudin-4, claudin-5, claudin-7, claudin-10, claudin-15, and claudin-18 have been reportedly expressed in the lung (31, 49) . However, the precise distribution of claudins in the lungs has not yet been determined. Moreover, the expression patterns of claudins after lung injury have not been clarified.
In the present study, we determined the expression pattern of claudins in the normal mouse lung and examined the alterations in the expression of claudins and other junction proteins after bleomycin administration. Mice were administered bleomycin by intraperitoneal injection, and not intratracheal injection, to avoid severe injury to alveolar epithelial cells (43) . Because transforming growth factor-␤ (TGF-␤) was found to be upregulated after lung injury, we examined the effects of TGF-␤ on the expression of junction molecules in cultured cells.
MATERIALS AND METHODS
Animals and bleomycin-induced pulmonary fibrosis. We purchased wild-type C57BL/6 mice and CrJ Wistar rats from Charles River (Japan, Yokohama). Pulmonary fibrosis was induced in the 10-to 12-wk-old female C57BL/6 mice by intraperitoneal instillation of 1.0 mg/body bleomycin chlorate (Nipponkayaku, Tokyo, Japan) dissolved in 0.1 ml of saline on alternate days for 7 days (days 1, 3, 5, and 7). On days 1 (control), 7, 14, and 28, the mice were anesthetized and killed. Animal experiments were conducted in accordance with the National Institutes of Health's Guide for the Care and Use of Laboratory Animals. This study was approved by the Institutional Animal Care and Use Committee of Tohoku University.
Antibodies. Rabbit anti-mouse polyclonal antibodies (pAb) against claudin-1, claudin-3, claudin-4, claudin-7, claudin-8, claudin-10, claudin-15, and claudin-18 and rat anti-mouse monoclonal antibody (mAb) against occludin (MOC37) were prepared and characterized as described previously (21, 38) . Claudin-18 pAb was affinity purified on nitrocellulose membranes with the corresponding glutathione S-transferase (GST) fusion peptide. Rabbit anti-mouse/human pAbs against claudin-3 and claudin-5, rabbit anti-mouse/rat pAb against claudin-4, and mouse anti-mouse/rat/human mAb against claudin-5 were purchased from Zymed Laboratories (San Francisco, CA); rat anti-mouse platelet endothelial cell adhesion molecule (PECAM) mAb from BD Pharmingen (Heidelberg, Germany); rat anti-mouse mAb against CD34 from AbD Serotec (Germany); goat anti-mouse PECAM pAb from Santa Cruz Biotechnology (Santa Cruz, CA); rabbit anti-mouse/ human pAb against ␤-actin from Abcam (Cambridge, UK); and mouse anti-␣-smooth muscle actin mAb (1A4) from Sigma Chemical (St. Louis, MO).
SDS-PAGE and immunoblotting.
Lysates of Escherichia coli expressing GST-claudin fusion proteins were subjected to one-dimensional SDS-PAGE. For immunoblotting, proteins were electrophoetically transferred from gels onto nitrocellulose membranes, which were then incubated with the first antibody. Bound antibodies were detected with biotinylated secondary antibodies and streptavidinconjucated alkaline phosphatase (Amersham Pharmacia Biotech). Nitroblue tetrazolium and bromochloroindolyl phosphates were used as the substrate for detection of alkaline phosphatase. Mice lung tissue in 3 ml RIPA buffer (containing 1% aprotinin, 2 mM phenylmethylsulfonyl fluoride, and 10 g/ml leupeptin) was homogenized at 4°C, incubated on ice for 5-10 min, and centrifuged at 5,000 g for 20 min at 4°C. Electrophoresis was performed using the Novex Tris-glycine gel system (Invitrogen, Carlsbad, CA). A volume of supernatant that contained 150 g protein was mixed with an equal volume of 2ϫ SDS sample buffer. The samples were boiled for 3 min and separated on 14% Novex Tris-glycine gels. The gels were electroblotted onto PVDF membranes. After being blocked with 5% skim milk, the blots were probed with rabbit anti-claudin-5 pAb (1:2,500), rabbit anticlaudin-18 pAb (not affinity purified; 1:5,000), rat anti-Occludin mAb (1:2,500), and rat anti-PECAM mAb (1:2,500) at room temperature for 1 h and subsequently incubated with peroxidase-conjugated anitrabbit or anti-rat antibody (1:5,000) for 1 h at room temperature. Signals were detected with the Amersham ECL kit. Rabbit anti-␤-actin antibody (1:2,500) was used as a loading control. ImageJ software was used to perform densitometric analysis.
Northern blotting. Total RNA from mouse organs was isolated using TRIzol reagent (Invitrogen) in accordance with the manufacturer's protocol. Aliquots of ϳ15 g of total RNA were separated on 1% formaldehyde/agarose gels, transferred onto positively charged nylon membranes, and cross-linked by ultraviolet irradiation. The RNA was hybridized with digoxigenin-labeled DNA probes according to the manufacturer's protocol (Roche, Mannheim, Germany). After being rinsed extensively, the membranes were incubated with the 1,2-dioxetane substrate CSPD (Tropix, Bedford, MA) and exposed to an X-ray film. The entire lengths of the open reading frames of the claudins were used as templates for the DNA probes, which were labeled using a digoxigenin DNA labeling kit (Roche).
In situ hybridization. Paraffin-embedded mouse lung tissue was cut into thin serial sections for investigating claudin-5 and claudin-18 expression. A region of the open reading frame of claudin-5 or claudin-18 was amplified using primers tagged with the T7 promoter sequence (antisense probe) and T3 promoter sequence (sense probe). Biotin-labeled RNA probes were prepared using an RNA labeling kit (Hoffmann-La Roche, Basel, Switzerland). Immunological detection and hybridized probe visualization were performed using a commercial kit (GenPoint; DakoCytomation, Tokyo, Japan).
Bronchoalveolar lavage and cell counts. Bronchoalveolar lavage (BAL) was obtained as described previously (7). Briefly, the lungs were lavaged twice with 0.75 ml of PBS. After centrifugation (2,300, 5 min), the supernatants were stored for cytokine analyses, and cell pellets were resuspended in 1 ml of PBS for total and differential cell counts. Total BAL cells were counted with a hemocytometer. The BAL differential was determined from Ն200 cells in Cytospin preparations stained with Diff-Quik (Sysmex), and the cells were identified as macrophages, eosinophils, lymphocytes, or neutrophils on the basis of cellular morphology and staining characteristics.
Collagen assay. The Sircol collagen assay (Biocolor, Belfast, UK) was performed following the manufacturer's instructions.
Quantitative real-time PCR. Total mRNA was extracted from the distal lung tissue of control mice and the resected lung tissue of the test mice on days 7, 14, and 28 after administration of bleomycin, as described above. Single-stranded cDNA was prepared from 2 g of total RNA by reverse transcription using random primers with a high-capacity cDNA reverse transcription kit (PE Applied Biosystems, Foster City, CA). Quantitative real-time PCR analysis was performed using the Step One Plus System (PE Applied Biosystems) with 2ϫ SYBER Green PCR Master Mix (PE Applied Biosystems) in accordance with the manufacturer's protocol. PCR was performed as follows: 40 cycles at 95°C for 15 s and 60°C for 1 min after preincubation at 95°C for 10 min. All primers are listed in Table 1 . Quantification of the reference (GAPDH) gene and target genes in each sample set was performed by the standard curve method. Changes in the mRNA expression level were determined after normalization to that of GAPDH mRNA.
ELISA. The levels of TGF-␤ (TGF-␤ 1) in BAL were measured using a commercial ELISA kit (Bender MedSystems, Vienna, Austria). Table 1 . Real-time PCR primers used in this study
Immunofluorescence microscopy. Mouse lungs in the thoracic cages were infused through the trachea with 60% optimal cutting temperature compound (Tissue-Tek; Miles Laboratories, Elkhart, IN) in PBS, removed, and frozen in liquid nitrogen. The tissues were cut into ϳ4-m-thick frozen sections using a cryostat. For immunofluorescence staining, the lungs were fixed with ice-cold 95% ethanol, followed by 100% acetone at room temperature for 1 min, and then washed three times in PBS. Cultured cells were fixed with 3% formaldehyde for 15 min, followed by 0.1% Triton X-100 for 3 min at room temperature, and then washed three times in PBS. After they were soaked in PBS containing 3% BSA, the sections were incubated with primary antibodies in a moist chamber for 1 h. They were then washed three times with PBS and incubated for 30 min with secondary antibodies and 4,6-diamino-2-phenylindole for nuclear staining. Furthermore, they were washed with PBS and observed under a fluorescence microscope (Olympus BX51; Olympus, Tokyo, Japan).
Cell culture. Mouse L cells and human A549 cells were cultured in DMEM supplemented with 10% FCS. Human umbilical vein endothelial cells (HUVECs) were purchased from Cambrex Bio Science Walkersville (Walkersville, MD) and cultured in endothelial cell growth medium-2 singlequots obtained from Clonetics (San Diego, CA).
Cell experimental conditions. A549 cells were stimulated with 5 ng/ml recombinant TGF-␤ (R&D Systems, Minneapolis, MN) at 24 h after transfer into serum-free medium. Confluent HUVECs were transferred into human endothelial serum-free medium (Invitrogen) with 10 ng/ml recombinant fibroblast growth factor-1 (R&D Systems) and 5 ng/ml recombinant epidermal growth factor (R&D Systems). After 24 h, the cells were stimulated with 5 ng/ml TGF-␤ (R&D Systems), 30 ng/ml vascular endothelial growth factor (VEGF; R&D Systems), or both.
Statistical analysis. Group comparisons were made by the rank sum test or Student's t-test. A value of P Ͻ 0.05 was deemed to indicate statistical significance.
RESULTS

Expression of claudin isoforms in mouse lungs.
We first examined the expression of all 24 claudin isoforms (claudins 1-24) in mouse lungs by Northern blotting to identify the most abundant claudins expressed in this tissue. Simultaneously, we also examined claudin gene expression in the mouse liver, kidney, and intestine ( Fig. 1) . We detected expression of claudin-1, claudin-3, claudin-4, claudin-5, claudin-7, claudin-8, claudin-10, claudin-12, claudin-15, claudin-17, claudin-18, claudin-22, and claudin-23 in the lung tissues. Among these, the expression of claudin-3, claudin-4, claudin-5, claudin-10, claudin-12, and claudin-18 was high, especially that of claudin-5 and claudin-18. In particular, among the organs investigated, only the lungs showed the presence of claudin-18. The expression patterns observed were similar to those determined by analysis of the expressed sequence tag counts found in the UniGene database (http://www.ncbi.nlm.nih. gov/UniGene).
Characterization of anti-claudin antibodies. To investigate the distribution of claudins in the lungs, the specificities of anti-claudin antibodies were examined. The antigens used to generate these claudin pAbs were C-terminal peptides of claudins with similar sequences and tertiary structures ( Fig. 2A) . To examine the specificities of anti-claudin pAb, immunoblotting analyses were performed using E. coli-expressed GST fusion proteins containing the cytoplasmic domains of claudins 1-24. Anti-claudin-18 pAb reacted only with claudin-18 in both immunoblotting and immunostaining experiments after affinity purification of claudin-18 pAb using specific peptides (Fig.  2B ). However, immunoblotting showed that rabbit anti-claudin-5 pAb reacted not only with the claudin-5 C-terminal peptide but also with the claudin-3 and claudin-4 C-terminal peptides (Fig. 2B ). This was confirmed by immunostaining with L-cell (mouse fibroblasts) transfectants expressing the claudins. Rabbit anti-claudin-5 pAb recognized not only L-cell transfectants expressing claudin-5 but also those expressing claudin-3 ( Fig. 2C) . Mouse anti-claudin-5 mAb reacted only with claudin-5 and could not be used for immunostaining mouse lung tissues because nonspecific signals were obtained.
Both claudin-5 and claudin-18 are expressed in the alveolar septa of mouse lungs. Occludin is considered to be a marker of the tight junctions of epithelial cells (9) . Anti-occludin mAb was found concentrated in sharp lines at cell-cell junctions of epithelial cells, and these lines were double stained with ZO-1. Anti-PECAM mAb was also found concentrated in lines at cell-cell junctions of endothelial cells, but no double staining with occludin was observed. PECAM was used as a marker of the junction between endothelial cells (Fig. 3) .
The immunolocalization of claudin-1, claudin-3, claudin-4, claudin-5, claudin-7, claudin-8, claudin-10, and claudin-18, which were shown to be expressed in mouse lungs by northern blotting (Fig. 1) , was examined in serial frozen sections of the mouse lung. No antibodies specific to claudin-12, claudin-17, claudin-22, and claudin-23 were available. Anti-occludin mAbs were concentrated in sharp lines at cell-cell junctions in both epithelial cells. Antibodies against claudin-1, claudin-3, claudin-4, claudin-3/5, claudin-7, and claudin-10 were concentrated in the airway cells, while those against claudin-3/5 and claudin-18 were concentrated in the alveolar septa. Immunostaining for claudin-4 was observed in a subset of epithelial 
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TIGHT JUNCTIONS AND LUNG INJURY cells; however, they did not form a sharp line at cell-cell junctions (Fig. 4) . Immunostaining with antibodies against claudin-3, claudin-4, claudin-7, and claudin-10 showed a linear pattern in the epithelial cells of the airways, and double staining with ZO-1 antibody was noted (Fig. 5) . Immunostaining with anti-claudin-3/5 antibody was localized in the epithelial cells of the alveolar septa (Fig. 6A) . Since claudin-3 immunostaining was localized in the airways but not in the alveolar septa, we assumed that at least claudin-5 was expressed in the alveolar septa. Claudin-18 immunostaining was concentrated only in the alveolar septa in the mouse lung (Fig. 6A) .
We validated these results using in situ hybridization because anti-claudin antibodies sometimes cross-react with other claudins. Both claudin-18 and claudin-5 anti-sense probes detected strong signals in the alveolar septa and only faint signals in the airways (Fig. 6B) .
We concluded that claudin-5 and claudin-18 are strongly expressed in the alveolar septa of mouse lungs.
Specific localization of claudin-5 and claudin-18 in the alveolar septa. Although both claudin-5 and claudin-18 showed linear staining patterns in the alveolar septa, only the patterns of claudin-18 were always colocalized with those of occludin. In contrast, most immunostaining patterns of claudin-5 were colocalized with the endothelial marker PECAM and not with occludin (Fig. 7A) . We further confirmed the specific localization of claudin-5 and claudin-18 using rat lungs. Frozen sections of rat lungs were double stained with mouse claudin-5 mAb and rabbit claudin-18 pAb. Although claudin-5 and claudin-18 showed linear staining patterns in the alveolar septa, they were not colocalized (Fig. 7B) . These results indicate that claudin-18 is the major claudin present in the tight junctions of alveolar epithelial cells and claudin-5 is distributed in capillary endothelial cells.
Pathological changes in mouse lungs after lung injury by bleomycin. We examined the effects of lung injury and subsequent fibrosis on the tight junctions of alveolar epithelial cells. Mice were administered bleomycin by intraperitoneal instillation to induce acute lung injury and pulmonary fibrosis. The lung tissues were examined on days 7, 14, and 28 after bleomycin-induced lung injury (2, 17) . On day 7, a slight increase was observed in the cellularity of the alveolar septa. On day 14, diffuse multifocal changes such as thickening of the alveolar septa and intraalveolar fibrosis with many fibroblasts as well as focal lesions of dense fibrosis developed. The changes on day 28 were almost the same as those observed on day 14, with the degree of severity varying considerably from mild to severe. Immunostainings for CD34 were decreased around fibrotic lesion. In alveolar septa of nonfibrous lesions, immunostaining pattern for CD34 was not altered, compared with alveolar septa of normal lung (Fig. 8A) . BAL cell analysis revealed the number of neutrophils was slightly increased at 7 days after bleomycin administration, which reflected mild alveolitis (Fig. 8B) . Although the number of total cells was increased, the number of neutrophils was not increased at a later time. Surfactant protein-D has been reported to be useful biomarker of interstitial lung disease (33) . Serum surfactant protein-D was increased continuously after bleomycin administration, which implied pulmonary fibrosis was progressive (Fig. 8C) .
Alterations in the levels of tight junction proteins in mouse lungs due to lung injury by bleomycin. We examined alterations of claudin-1, claudin-3, claudin-4, claudin-5, claudin-7, claudin-10, claudin-12, claudin-18, ZO-1, and occludin expression by quantitative real-time reverse transcription PCR. Expression of claudin mRNAs was normalized to GAPDH. All primer pairs produced amplicons of the predicted size. Quantitative RT-PCR revealed that expression of claudin-3, claudin-5, and claudin-18 was highest compared with the other claudin isoforms in the normal lung. After bleomycin-induced lung injury, the expression of all claudins, particularly that of claudin-18, decreased (Fig. 9A) . These alterations were statistically significant, except ZO-1.
Alterations in the tight junction molecules of mouse lungs were evaluated at each time point by quantitative RT-PCR (n ϭ 4). The relative expression level of claudin-5 and clau- din-18 mRNA decreased on day 7 and gradually recovered on days 14 and 28. The relative expression of occludin also decreased on day 7, and downregulation of occludin were prolonged to day 28 (Fig. 9B) . Semiquantitative immunoblotting (n ϭ 5) revealed that claudin-5 and claudin-18 protein was not markedly attenuated on day 7, i.e., in the acute stage. In contrast, occludin protein decreased significantly by day 7. On day 28, i.e., in the late stage, amount of claudin-5, claudin-18, and occludin decreased compared with that in the control mouse lung (Fig. 9, C and D) .
Alterations in the immunostaining pattern of tight junction molecules of mouse lungs in bleomycin-induced lung injury.
On immunofluorescence staining of claudin-18 and occludin in nonfibrotic areas, the occludin signals were attenuated but the claudin-18 signals were not attenuated until day 14. In the fibrotic lesions, the signals for occludin and claudin-18 were colocalized as dot-like patterns on day 14. This observation suggests that the tight junctions of epithelial cells might lose their integrity in fibrotic lesions (Fig. 9E) .
Effects of TGF-␤ on tight junction molecules expression in cultured cells.
We investigated the factors influencing the expression of tight junction molecules in lung injury. TGF-␤ is a critical mediator of lung fibrosis after injury. The TGF-␤ levels in BAL increased in the lungs of mice that were intraperitoneally administered bleomycin (Fig. 10A) . The epithelial-mesenchymal transition (EMT) was induced when TGF-␤ was added to cultured human alveolar epithelial cells (A549). The staining pattern of occludin at 48 h after the addition of TGF-␤ to serum-free medium indicated disrupted tight junctions. Tight junctions were not detected 72 h later, but ␣-smooth muscle actin expression was increased (Fig. 10B) . Upregulation of ␣-smooth muscle actin expression indicated EMT. In cultured HUVECs, the immunostaining patterns for claudin-5 and PECAM were concentrated at cell-cell junctions (Fig. 10C) . When the cells were cultured with TGF-␤, only weak attenuation of claudin-5 signals was observed at the cell-cell junctions. In contrast, the level of claudin-5 immunostaining was enhanced when the cells were cultured with a low concentration of VEGF. Moreover, TGF-␤ inhibited the VEGF-induced increase in the level of claudin-5 when the cells were cultured with both TGF-␤ and VEGF. This observation of the level of claudin-5 was confirmed by immunoblotting of HUVEC lysates. The level of claudin-5 decreased when HUVECs were cultured with TGF-␤ and increased when they were cultured with VEGF. Furthermore, TGF-␤ inhibited the VEGF-induced increase in claudin-5 expression significantly (Fig. 10, D and E) .
DISCUSSION
The results of the present study indicate that claudin-5 and claudin-18 are strongly expressed in lung tissues, especially in the alveolar septa; claudin-5 is expressed in capillary endothelial cells and claudin-18 in the alveolar epithelial cells. Furthermore, we demonstrated that the expression of claudin-5 and claudin-18 decreased after lung injury, suggesting that the tight junctions of endothelial cells and alveolar epithelial cells were severely affected by bleomycin. We also found that TGF-␤, a key regulator of fibrosis, disrupted tight junctions of epithelial and endothelial cells, indicating that TGF-␤ may partially disrupt tight junctions.
Claudin-5 was predominantly expressed in the cell-cell junctions of alveolar endothelial cells. Claudin-5 was identified as an endothelial cell-specific component of tight junction strands, consistent with data reported by Morita et al. (28) . However, it was also reported to be expressed by alveolar epithelial cells (49) . This discrepancy may have been due to the weak expression of claudin-5 at the protein level or the lack of specificity of claudin-5 antibodies. Another possibility is that when cultured in vitro, alveolar epithelial cells may easily change their patterns of expression of junction proteins, including claudins (23) . We examined the specificity of anti-claudin antibodies by immunoblotting the C-terminal peptides of claudins 1-24 and immunostaining for L-cell transfectants expressing the 24 claudin isoforms. Immunostaining with specific antibodies and in situ hybridization showed strong expression of claudin-5 in endothelial cells, suggesting that this claudin specifically localizes in the cell-cell junctions of endothelial cells in normal lungs.
Claudin-18 was predominantly expressed in the tight junctions of alveolar epithelial cells. We also identified claudin-18 as one of the major components of the tight junctions of alveolar epithelial cells. The lines positive for occludin were completely double stained with claudin-18, but those positive for PECAM were not. Claudin-18 expression was previously reported to be specific to the lung and stomach (31) , and in this study, we further determined its limited localization in alveolar epithelial cells. Other claudins, i.e., claudin-1, claudin-3, claudin-4, claudin-7, claudin-8, and claudin-10, were not strongly expressed in the alveolar septa. Immunostaining with anticlaudin-4 antibody showed only a weak signal in a subset of alveolar cells, while immunostaining with anti-claudin-1, anticlaudin-3, anti-claudin-7, anti-claudin-8, and anti-claudin-10 antibodies showed no significant signals that merged with those of occludin in the alveolar septa. Our results showed that the expression of claudin-1, claudin-3, claudin-4, claudin-7, claudin-8, and claudin-10 was considerably low in the alveolar septa, although Kaarteenaho-Wiik and Soini (18) reported the expression of claudin-3, claudin-4, and claudin-7 in human pneumocytes by immunohistochemistry. Altered expression of tight junction molecules after lung injury might cause alveolar wall dysfunction. We hypothesized that the altered expression of tight junction molecules after lung injury might contribute to alveolar barrier dysfunction, similar to the epithelial barrier dysfunction in inflammatory bowel disease. Intestinal barrier dysfunction is not only caused by apoptotic leaks but also by tight junction impairment (42) . The normal alveolar barrier comprises the capillary and alveolar epithelium. From observations in occludin knockout mice, Saitou et al. (38) showed that claudin, but not occludin, contributed to the epithelial barrier function of tight junctions.
The barrier of the endothelium consists of claudin-5, which controls the pericelluar permeability of endothelial cells (32) . The alveolar epithelial barrier prevents cells and fluid from flooding the air space and is also involved in the active transport of ions and solutes, a process essential for edema fluid clearance. In severe lung injury, alveolar type I cells in the alveolar epithelium undergo apoptosis, thus hampering the transport of ions and solutes. These changes are thought to cause alveolar flooding. In contrast, in mild-to-moderate lung injury, necrosis of alveolar type I cells is not pronounced (1) . The alveolar epithelium is remarkably resistant to apoptosis induced by chemical injury, especially compared with the adjacent lung endothelium. Although apoptosis of epithelial cells was the major cause of alveolar barrier dysfunction, altered expression of junction proteins might also contribute to its dysfunction.
Alterations in claudin expression after lung injury with bleomycin. Quantitative RT-PCR demonstrated that expression of tight junction proteins was downregulated after lung injury with bleomycin. The results of Western blotting showed that the levels of claudin-5, claudin-18, and occludin decreased after lung injury with bleomycin. We previously showed proliferation of CD34-positive alveolar capillaries in nonfibrotic lesions of IPF lungs; however, we (8) found CD34-positive capillaries were not increased in nonfibrotic lesions in bleomycin-induced pulmonary fibrosis model. This result might explain why claudin-5, which was expressed in endothelial cells, was decreased in bleomycin-induced pulmonary fibrosis model, while a previous study (18) reported that expression of claudin-5 was upregulated in IPF lungs.
Bleomycin impaired the alveolar epithelial barrier. Based on our results demonstrating that claudin-18 is highly specific to tight junctions of alveolar epithelial cells, we conclude that bleomycin primarily injured alveolar epithelial cells, thereby impairing the alveolar epithelial barrier. In the late phase of lung injury in this model, the level of claudin-18 decreased significantly and its pattern of immunostaining changed from a linear to dot-like appearance in the adjacent fibrotic lesions, suggesting loss of integrity of the epithelial tight junctions.
Recently, Cohen et al. (5) showed that claudin-18 and occludin expression was downregulated in alveolar epithelial cells isolated from septic animal. Kaarteenaho-Wiik et al. and Soini (18) reported altered claudin expression in lungs of usual interstitial pneumonia patients. According to their reports, the expression pattern in the metaplastic alveolar epithelium was different from that in the normal alveolar epithelium. Analysis of other claudins, except claudin-18, was limited to the alteration of mRNA of eight claudins. Further studies are required for a better understanding of these processes.
The potential significance of alteration in claudin expression during the late phase is still unclear. Although there were some explanations, we speculate that it is related with acute deterioration of interstitial pneumonia. Golebiweski et al. (11) reported that influenza virus, which bound to tight junction components, disrupted the cellular tight junction and caused severe disease. The alteration in claudin expression might allow the influenza virus to access tight junction components. Systemic inflammation causes sustained disruption of tight junction proteins and exacerbation of ischemic brain injury (26) . Similarly, a sustained disruption of claudin-5 after lung injury might cause exacerbation of lung injury.
EMT might occur after lung injury. In lung injury, EMT might induce the disruption of tight junctions and modulate the barrier function of epithelial cells; EMT has been shown to induce the destruction of tight junctions of cultured cells (16) . EMT describes the differentiation switch between polarized epithelial cells and contractile and motile mesenchymal cells. During EMT, epithelial cells lose their epithelial properties, including the ability to form tight junctions and gain mesenchymal properties (29) . In renal fibrosis, EMT has been reported to play a critical role, and a significant number of myofibroblasts are known to arise during EMT of tubular epithelial cells (30) . EMT is also thought to occur in pulmonary fibrosis (4) . In a pulmonary fibrosis model induced by bleomycin, some of the myofi- broblasts were found to be derived from alveolar epithelial cells as the result of EMT (53) . Incomplete expression of EMT markers was observed in hyperplastic pneumocytes and bronchiolar basal metaplastic cells in lungs of IPF patients. Complete EMT seemed to be specific for usual interstitial pneumonia lesions (27) . Carrozzino et al. (3) showed that even an incomplete EMT could modulate the ionic permeability of tight junctions of cultured epithelial cells. We speculate that both incomplete and complete EMT in pulmonary fibrosis can modulate the barrier function of epithelial cells.
TGF-␤ may play a pivotal role in the disruption of epithelial and endothelial tight junctions. Since TGF-␤ is a critical mediator of both lung injury and pulmonary fibrosis (36), we believe that the abovementioned alterations in the tight junctions due to lung injury may have been partly mediated by TGF-␤.
In our previous study (43) , using ELISA, we demonstrated that the activity of TGF-␤ increased in BAL after bleomycininduced lung injury. Furthermore, Kaminski et al. (19) showed that TGF-␤ expression was upregulated in pulmonary fibrosis from the acute stage to the chronic stage.
Although some studies (13) have indicated that TGF-␤ upregulated the expression of tight junction proteins and strengthened the barrier function of epithelial cells, others (20, 24, 47, 52) have reported that TGF-␤ downregulated tight junction molecules by apoptosis or EMT in cultured epithelial cells. The effects of TGF-␤ are dependent on cell types and context (39) . Undevia et al. (48) showed that TGF-␤ could protect human airway epithelial cells from apoptosis and this antiapoptotic pathway was mediated by the Smad pathway involving the cyclin-dependent kinase inhibitor p21. Considering these findings, we speculate that TGF-␤ functions as an antiapoptotic cytokine and protects the epithelial cells in the acute phase; it also functions as the chief mediator of fibrosis and contributes to the disruption of cell-cell junctions of both epithelial and endothelial cells in the late phase.
In the present study, we confirmed that TGF-␤ disrupted the tight junctions of both alveolar epithelial cells and endothelial cells in vitro. When TGF-␤ was added to cultured epithelial cells (A549), EMT was induced and tight junctions were disrupted. TGF-␤ also decreased the expression of the endothelial junction molecule claudin-5 in cultured HUVECs; however, it did not affect the expression of PECAM. Our results are supported by previous studies demonstrating that TGF-␤ decreased the expression of claudin-5 in cultured embryonic stem cell-derived endothelial cells (50, 51) and that TGF-␤ did not alter PECAM expression in HUVECs (37) . In addition, Ota et al. (34) reported that the activin receptor-like kinase-5, a TGF-␤ receptor, decreased claudin-5 expression.
In conclusion, our results indicate that pathogenic alterations in epithelial and endothelial tight junctions occur during lung injury and subsequent fibrosis. TGF-␤, the chief mediator of fibrosis, plays a pathogenic role in fibrogenesis after lung injury and may disrupt the alveolar epithelial and endothelial tight junctions.
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No conflicts of interest, financial or otherwise are declared by the author(s). Fig. 10 . Transforming growth factor-␤ (TGF-␤) disrupted tight junctions of A549 and HUVECs A: TGF-␤ was upregulated in fibrotic lungs. TGF-␤ in bronchoalveolar lavage fluid was measured by ELISA on days 7, 14, and 28 after initiation of bleomycin administration Data are means Ϯ SE; n ϭ 3 mice per group. *P Ͻ 0.05. B: A549 cells treated with TGF-␤ (5 ng/ml) for 48 and 72 h were analyzed by immunofluorescence staining. By 48 h, occludin, one of the tight junction components, lost its linear staining pattern at the cell-cell junctions. By 72 h, occludin was not detectable at the junctions. Cells were fixed with 3% formaldehyde and stained for occludin (green) and ␣-smooth muscle actin (␣-SMA; red). Nuclei were stained with DAPI. Arrows indicate tight junctions. C: human umbilical vein endothelial cells (HUVECs) cultured with TGF-␤ (5 ng/ml), vascular endothelial growth factor (VEGF; 30 ng/ml), or a combination of both for 48 h were analyzed by immunofluorescence staining. Claudin-5 signals were attenuated mildly, although those of PECAM did not change when HUVECs were cultured with TGF-␤. Cells were fixed with 3% formaldehyde and double stained for claudin-5 (red) and PECAM (green). Nuclei were stained with DAPI. Arrows indicate cell-cell junctions. D: lysates prepared from HUVECs were analyzed by immunoblotting with anti-claudin-5 mAb. HUVECs were cultured for 48 h with TGF-␤ (5 ng/ml), VEGF (30 ng/ml), or a combination of both. TGF-␤ reduced the level of claudin-5 and inhibited the VEGF-induced increase in the level of claudin-5. E: semiquantitative immunoblotting analysis also showed that TGF-␤ reduced the level of claudin-5 and inhibited the VEGF-induced increase in the level of claudin-5. Data are means Ϯ SE; n ϭ 5 per group. *P Ͻ 0.05.
